Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Blast Crisis 4Unspecified Adult Solid Tumor, Protocol Specific 3Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Gliosarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Anemia, Refractory, with Excess of Blasts 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1

Interventions

fludarabine phosphate 14Whole-Body Irradiation 8Mycophenolic Acid 8Peripheral Blood Stem Cell Transplantation 7Cyclosporine 6Cyclophosphamide 6Cytarabine 5Azacitidine 4Thiotepa 3Tacrolimus 3Filgrastim 3Antilymphocyte Serum 3tipifarnib 2laromustine 2aldesleukin 2Methylprednisolone 2Etoposide 2Cyclosporins 2Cord Blood Stem Cell Transplantation 2Bortezomib 2Biopsy 24-phenylbutyric acid 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2venetoclax 1sargramostim 1lintuzumab 1itacitinib 1ispinesib 1ilorasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Refractory, with Excess of Blasts × tipifarnib × Clear all
NCT00005845 2013-12-16

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
65 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

NCT00005967 2013-02-11

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡